Natera

Partner Level

Gold

Company Headquarters

201 Industrial Rd.
Suite 410
San Carlos, CA 94070

Website

Visit Site

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Look deeper at https://www.natera.com/oncology/signatera-advanced-cancer-detection/.